Therapy (HCV)

Lymphoblastoid IFN-(alpha)n1 Promising for Hepatitis C

Published in Hepatitis Weekly, May 4th, 1998

Lymphoblastoid interferon alpha-n1 appears to be more effective than interferon alpha-2b in treating chronic hepatitis C virus patients, according to the results of an international randomized controlled trial.

However, the trial - the largest reported to date comparing the short-term and long-term efficacy of lymphoblastoid interferon with recombinant interferon alpha (IFN-(alpha)) - reported an overall sustained alanine aminotransferase (ALT) response of just 10 percent of all treated patients.

"The reasons for the relatively disappointing results in the present trials were not apparent from a consideration of the pretreatment demographic and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-05-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry